Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease.

Publication ,  Journal Article
Kashyap, VS; Lakin, RO; Campos, P; Allemang, M; Kim, A; Sarac, TP; Hausladen, A; Stamler, JS
Published in: Journal of Vascular Surgery
July 2017

Endothelial function is improved by l-arginine (l-arg) supplementation in preclinical and clinical studies of mildly diseased vasculature; however, endothelial function and responsiveness to l-arg in severely diseased arteries is not known. Our objective was to evaluate the acute effects of catheter-directed l-arg delivery in patients with chronic lower extremity ischemia secondary to peripheral arterial disease.The study enrolled 22 patients (45% male) with peripheral arterial disease (mean age, 62 years) requiring lower extremity angiography. Endothelium-dependent relaxation of patent but atherosclerotic superficial femoral arteries was measured using a combination of intravascular ultrasound (IVUS) imaging and a Doppler FloWire (Volcano Corporation, Rancho Cordova, Calif) during the infusion of incremental acetylcholine (10-6 to 10-4 molar concentration) doses. Patients received 50 mg (n = 3), 100 mg (n = 10), or 500 mg (n = 9) l-arg intra-arterially, followed by repeat endothelium-dependent relaxation measurement (limb volumetric flow). IVUS-derived virtual histology of the culprit vessel was also obtained. Endothelium-independent relaxation was measured using a nitroglycerin infusion. Levels of nitrogen oxides and arginine metabolites were measured by chemiluminescence and mass spectrometry, respectively.Patients tolerated limb l-arg infusion well. Serum arginine and ornithine levels increased by 43.6% ± 13.0% and 23.2% ± 10.3%, respectively (P < .005), and serum nitrogen oxides increased by 85% (P < .0001) after l-arg infusion. Average vessel area increased by 6.8% ± 1.3% with l-arg infusion (acetylcholine 10-4; P < .0001). Limb volumetric flow increased in all patients and was greater with l-arg supplementation by 130.9 ± 17.6, 136.9 ± 18.6, and 172.1 ± 24.8 mL/min, respectively, for each cohort. Maximal effects were seen with l-arg at 100 mg (32.8%). Arterial smooth muscle responsiveness to nitroglycerin was intact in all vessels (endothelium-independent relaxation, 137% ± 28% volume flow increase). IVUS-derived virtual histology indicated plaque volume was 14 ± 1.3 mm3/cm, and plaque stratification revealed a predominantly fibrous morphology (46.4%; necrotic core, 28.4%; calcium, 17.4%; fibrolipid, 6.6%). Plaque morphology did not correlate with l-arg responsiveness.Despite extensive atherosclerosis, endothelial function in diseased lower extremity human arteries can be enhanced by l-arg infusion secondary to increased nitric oxide bioactivity. Further studies of l-arg as a therapeutic modality in patients with endothelial dysfunction (ie, acute limb ischemia) are warranted.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Vascular Surgery

DOI

EISSN

1097-6809

ISSN

0741-5214

Publication Date

July 2017

Volume

66

Issue

1

Start / End Page

187 / 194

Related Subject Headings

  • Vasodilator Agents
  • Vasodilation
  • Ultrasonography, Interventional
  • Ultrasonography, Doppler, Duplex
  • Treatment Outcome
  • Time Factors
  • Regional Blood Flow
  • Prospective Studies
  • Plaque, Atherosclerotic
  • Peripheral Arterial Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kashyap, V. S., Lakin, R. O., Campos, P., Allemang, M., Kim, A., Sarac, T. P., … Stamler, J. S. (2017). The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. Journal of Vascular Surgery, 66(1), 187–194. https://doi.org/10.1016/j.jvs.2016.12.127
Kashyap, Vikram S., Ryan O. Lakin, Patricia Campos, Matthew Allemang, Ann Kim, Timur P. Sarac, Alfred Hausladen, and Jonathan S. Stamler. “The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease.Journal of Vascular Surgery 66, no. 1 (July 2017): 187–94. https://doi.org/10.1016/j.jvs.2016.12.127.
Kashyap VS, Lakin RO, Campos P, Allemang M, Kim A, Sarac TP, et al. The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. Journal of Vascular Surgery. 2017 Jul;66(1):187–94.
Kashyap, Vikram S., et al. “The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease.Journal of Vascular Surgery, vol. 66, no. 1, July 2017, pp. 187–94. Epmc, doi:10.1016/j.jvs.2016.12.127.
Kashyap VS, Lakin RO, Campos P, Allemang M, Kim A, Sarac TP, Hausladen A, Stamler JS. The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. Journal of Vascular Surgery. 2017 Jul;66(1):187–194.
Journal cover image

Published In

Journal of Vascular Surgery

DOI

EISSN

1097-6809

ISSN

0741-5214

Publication Date

July 2017

Volume

66

Issue

1

Start / End Page

187 / 194

Related Subject Headings

  • Vasodilator Agents
  • Vasodilation
  • Ultrasonography, Interventional
  • Ultrasonography, Doppler, Duplex
  • Treatment Outcome
  • Time Factors
  • Regional Blood Flow
  • Prospective Studies
  • Plaque, Atherosclerotic
  • Peripheral Arterial Disease